Brussels (BELGIUM), October 26, 2007 at 7:00 am CET - Phase III clinical trials of UCB’s antiepileptic drug (AED) in development, brivaracetam, are underway, as adjunctive therapy in patients with refractory partial-onset epilepsy. Rikelta™ is the proposed tradename for brivaracetam.
